Blog: Our Insights
Your resource for industry news and updates from Broughton.

Paul Hardman

Paul has vast experience in inhaled product development across pharmaceutical and consumer products. He commenced his career working at a specialty pharmaceutical company where he gained experience of dry powder and metered dose inhaler development including treating local lung conditions and for systemic absorption for all stages of product development and commercial scale up. He also managed and successfully led the Quality Control department in a multinational pharmaceutical company that manufactured generic nicotine lozenges. Paul led the product characterisation team at Imperial Brands, where he designed the testing strategy for the chemistry of inhaled and oral next generation nicotine products assessing a variety of prototypes at the early stages of development and for regulatory submissions, including PMTA. He joined Broughton in 2021 as Head of Scientific Affairs and is responsible for consulting on and developing next generation nicotine product testing strategies for clients.

Recent Posts

ENDS companies left in the lurch

September 20, 2021

Broughton Head of Scientific Affairs, Paul Hardman has recently published an article with leading sector publication Tobacco Reporter.

Deficiency letters - common causes and how to ...

August 5, 2021

Broughton Head of Scientific Affairs, Paul Hardman has today published an article with leading sector publication Tobacco Reporter that ...

FDA PMTA 90-day deficiency letters – what next?

June 1, 2021

Broughton Head of Scientific Affairs, Paul Hardman outlines factors that can lead to data gaps in Premarket Tobacco Product  Applications ...
Contact us

From basic questions to complex compliance inquiries, we're here to help! Contact us today.